Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.

Journal Article (Letter;Multicenter Study)

Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.

Full Text

Duke Authors

Cited Authors

  • Forbes, LR; Vogel, TP; Cooper, MA; Castro-Wagner, J; Schussler, E; Weinacht, KG; Plant, AS; Su, HC; Allenspach, EJ; Slatter, M; Abinun, M; Lilic, D; Cunningham-Rundles, C; Eckstein, O; Olbrich, P; Guillerman, RP; Patel, NC; Demirdag, YY; Zerbe, C; Freeman, AF; Holland, SM; Szabolcs, P; Gennery, A; Torgerson, TR; Milner, JD; Leiding, JW

Published Date

  • November 2018

Published In

Volume / Issue

  • 142 / 5

Start / End Page

  • 1665 - 1669

PubMed ID

  • 30092289

Pubmed Central ID

  • PMC6322659

Electronic International Standard Serial Number (EISSN)

  • 1097-6825

Digital Object Identifier (DOI)

  • 10.1016/j.jaci.2018.07.020


  • eng

Conference Location

  • United States